Daré Bioscience, Inc. (DARE) Stock
DARE Key Statistics
About Daré Bioscience, Inc.
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
CEO: Sabrina Martucci Johnson. Company website
DARE — Frequently Asked Questions
What is the DARE stock price today?
Daré Bioscience, Inc. (DARE) trades at $0.90, down 34.00% on the day, as of Sep 20, 2026 15:00 UTC.
What is Daré Bioscience, Inc.'s market cap?
Daré Bioscience, Inc. has a market capitalisation of $8.61M, calculated from the live DARE share price and shares outstanding.
What is the P/E ratio of DARE?
DARE has no meaningful price-to-earnings ratio: Daré Bioscience, Inc. lost $1.33 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Daré Bioscience, Inc. make?
Daré Bioscience, Inc. generated revenue of $1.03M over the trailing twelve months, which puts the stock at 8.36 times sales.
What is the 52-week range for DARE?
DARE has traded between $0.78 and $3.78 over the past 52 weeks, and the last price is 76.1% below that high.
Is Daré Bioscience, Inc. profitable?
No. Daré Bioscience, Inc. is loss-making, with a net margin of -1,300.66% over the trailing twelve months.
What is the analyst price target for DARE?
Wall Street analysts rate DARE Buy, with an average price target of $12.00, 1,227.1% above the current price.
What sector is Daré Bioscience, Inc. in?
Daré Bioscience, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Daré Bioscience, Inc.?
Sabrina Martucci Johnson is the chief executive of Daré Bioscience, Inc., which employs 21 people.
Where can I track DARE in real time?
QFI Terminal shows DARE with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See DARE live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open DARE in Terminal See plans